In a meta-analysis of clinical studies involving patients with type 2 DM (T2DM), plasma renin activity remained significantly higher in patients using SGLT2 inhibitors for ≤ 3 months [17]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.